Evidence map›Paper›PMID 28219927›Full record

ArticleThe EMBO journal2017

Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.

Leonie Smeenk, Maria Fischer, Sabine Jurado, Markus Jaritz, Anna Azaryan, Barbara Werner, Mareike Roth, Johannes Zuber, Martin Stanulla, Monique L den Boer and 3 more

Open access · greenAbstract read
In one paragraph

Article in The EMBO journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. The Pleiotropy ofInternational journal of molecular sciences · 2022
    Review
  15. Childhood B-Cell Preleukemia Mouse Modeling.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Article
  18. Frontiers in oncology · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Leonie SmeenkResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Maria FischerResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Sabine JuradoResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Markus JaritzResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Anna AzaryanResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Barbara WernerResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Mareike RothResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Johannes ZuberResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
Martin StanullaPediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Monique L den BoerDepartment of Pediatric Oncology and Hematology, Erasmus Medical Center, Sophia Children Hospital, Rotterdam, The Netherlands.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sabine StrehlChildren's Cancer Research Institute, St. Anna Kinderkrebsforschung e.V., Vienna, Austria.
Meinrad BusslingerResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria busslinger@imp.ac.at.ORCID 0000-0002-9111-9351
Research Institute of Molecular Pathology · ATErasmus MC - Sophia Children’s Hospital · NLMedizinische Hochschule Hannover · DESt Anna Children's Hospital · ATSt. Jude Children's Research Hospital · US

Funding

Austrian Science Fund FWF P 21604European Research Council 291740
6 · The paper itself

Abstract

PAX5 is a tumor suppressor in B-ALL, while the role of PAX5 fusion proteins in B-ALL development is largely unknown. Here, we studied the function of PAX5-ETV6 and PAX5-FOXP1 in mice expressing these proteins from the

Indexed as

AnimalsETS Translocation Variant 6 ProteinForkhead Transcription FactorsMiceOncogene ProteinsPAX5 Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-etsRecombinant Fusion ProteinsRepressor ProteinsETS Translocation Variant 6 ProteinForkhead Transcription FactorsFoxp1 protein, mouseOncogene ProteinsPax5 protein, mousePAX5 Transcription FactorProto-Oncogene Proteins c-etsRecombinant Fusion ProteinsRepressor ProteinsB‐cell leukemiaCDKN2A/B cooperationmouse modelPAX5‐ETV6regulated target genes

Identifiers

PMID28219927
PMCPMC5350564
OpenAlexW2589670416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.